POSTmark™ AVV

Our Platform Optimized for Scale-up and Transfer (POSTmark) is designed with mirrored R&D and cGMP equipment and processes, streamlining the pathway from research and development to large-scale, good manufacturing practice (cGMP) production. This platform supports every phase of development, ensuring a seamless transition from initial R&D to cGMP scale.

With POSTmark, cGMP-grade adeno-associated virus (AAV) production can be achieved within 6–9 months, and research-grade AAV products closely replicate those produced at cGMP standards, enabling consistent and reliable results. By mirroring processes at each stage, POSTmark reduces time, costs, and associated risks, offering an efficient and scalable solution for AAV development and production.